Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Synergistic Effect of Carfilzomib and Metformin in Vascular Plasticity; The Emerging Role of Autophagy

Panagiotis Efentakis, PhD, Ioanna Andreadou, PhD, Panagiota-Efstathia Nikolaou, PhD, Claudius Witzler, Svenja Siemer, Eftathios Kastritis, Philip Wenzel, MD PhD, Meletios A. Dimopoulos, MD, Evangelos Terpos, MD PhD

Blood (2019) 134 (Supplement_1): 3797.

https://doi.org/10.1182/blood-2019-123522

Published: 2019

Journal Articles

Next Generation Flow Cytometry Provides a Standardized, Highly Sensitive and Informative Method for the Analysis of Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma: A Single Center Study in 182 Patients

Evangelos Terpos, MD PhD, Ioannis V. Kostopoulos, Aristea-Maria Papanota, MD, Konstantinos Papadimitriou, BSc, Panagiotis Malandrakis, MD, Paraskevi Micheli, BSc, Ioannis Ntanasis-Stathopoulos, MD, Despina Fotiou, MD, Andreas Metousis, BSc, Nikolaos Kanellias, MD, Magdalini Migkou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Maria Gavriatopoulou, MD, Eftathios Kastritis, Ourania E. Tsitsilonis, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 4338.

https://doi.org/10.1182/blood-2019-127989

Published: 2019

Journal Articles

The Genomic and Transcriptomic Landscape of Double-Refractory Multiple Myeloma

Bachisio Ziccheddu, PhD, Giulia Biancon, Chiara De Philippis, MD, Filippo Bagnoli, MD, Francesco Maura, MD, Matteo Dugo, Andrea Devecchi, Loris De Cecco, Marialuisa Sensi, Carolina Terragna, Marina Martello, Tina Bagratuni, PhD, Eftathios Kastritis, Meletios A. Dimopoulos, MD, Michele Cavo, Cristiana Carniti, PhD, Vittorio Montefusco, Paolo Corradini, Niccolo Bolli, MD PhD

Blood (2019) 134 (Supplement_1): 3056.

https://doi.org/10.1182/blood-2019-122197

Published: 2019

Journal Articles

Outcomes of Patients with t(11;14) Multiple Myeloma: An International Myeloma Working Group Multicenter Study

Blood (2019) 134 (Supplement_1): 3066.

https://doi.org/10.1182/blood-2019-126867

Published: 2019

Journal Articles

Longitudinal T Cell Immunoprofiling of Patients with Relapsed and/or Refractory Myeloma Who Receive Daratumumab Monotherapy: A Subanalysis of a Phase 2 Study (the REBUILD Study)

Elisavet Vlachonikola, Anna Vardi, MD PhD, Eftathios Kastritis, Evdoxia Hatjiharissi, Eirini Katodritou, MD, Alexandra Siorenta, MD, Electra Sofou, Konstantia Kotta, Maria Karipidou, Maria Gavriatopoulou, MD, Sosana Delimpasi, MD, Argiris Symeonidis, MD PhD, Kostas Stamatopoulos, Meletios A. Dimopoulos, MD, Evangelos Terpos, MD PhD, Anastasia Chatzidimitriou

Blood (2019) 134 (Supplement_1): 3167.

https://doi.org/10.1182/blood-2019-124655

Published: 2019

Journal Articles

Consolidation with Carfilzomib, Lenalidomide and Dexamethasone (KRd) Following ASCT Results in High Rates of Minimal Residual Disease Negativity and Improves Bone Metabolism, in the Absence of Bisphosphonates, Among Newly Diagnosed Patients with Multiple Myeloma

Maria Gavriatopoulou, MD, Evangelos Terpos, MD PhD, Ioannis Ntanasis-Stathopoulos, MD, Panagiotis Malandrakis, MD, Evangelos Eleutherakis-Papaiakovou, MD, Athanasios Papatheodorou, PhD, Nikolaos Kanellias, MD, Magdalini Migkou, MD, Despina Fotiou, MD, Ioanna Dialoupi, MD, Maria Roussou, MD, Nikoletta-Aikaterini Kokkali, Eftathios Kastritis, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 3118.

https://doi.org/10.1182/blood-2019-123916

Published: 2019

Journal Articles

Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients

Morie A Gertz, MD, Adam D. Cohen, MD, Raymond L Comenzo, MD, Charles Du Mond, Eftathios Kastritis, Heather J Landau, MD, Edward N. Libby, III, MD, Michaela Liedtke, MD, Giampaolo Merlini, MD, Vaishali Sanchorawala, MD, Stefan O. Schönland, MD, Ashutosh D Wechalekar, MBBS, MD FRCP, FRCPath, DM, Jeffrey A. Zonder, Gene Kinney, PhD

Blood (2019) 134 (Supplement_1): 3166.

https://doi.org/10.1182/blood-2019-124482

Published: 2019

Journal Articles

Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Is a Renal Biomarker with Potential Clinical Applications in Monoclonal Gammopathy of Renal Significance (MGRS)

Eftathios Kastritis, Ioannis Papassotiriou, PhD, Maria Roussou, MD, Maria Gavriatopoulou, MD, Mantzou Aimilia, PhD, Erasmia Psimenou, MD, Smaragdi Marinaki, Charikleia Gakiopoulou, MD, Alexandra Margeli, PhD, Nikolaos Kanellias, MD, Magdalini Migkou, MD, Despina Fotiou, BMBS, MA, Ioannis Ntanasis-Stathopoulos, MD, Gerasimos-Petros Papassotiriou, PhD, Aristea-Maria Papanota, MD, Evangelos Terpos, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 3126.

https://doi.org/10.1182/blood-2019-125305

Published: 2019

Journal Articles

High-Dimensional Heterogeneity of Waldenström Macroglobulinemia within Its Immune Tumor Microenvironment

Jana Jakubikova, PhD, Danka Cholujova, PhD, Gabor Beke, PhD, Zachary R Hunter, PhD, Teru Hideshima, MD PhD, Ludmila Flores, Merav Leiba, MD, Paul G. Richardson, MD, Eftathios Kastritis, David M. Dorfman, MD PhD, Steven P Treon, MD PhD FRCP, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 3975.

https://doi.org/10.1182/blood-2019-130011

Published: 2019

Journal Articles

OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis

Giovanni Palladini, MD PhD, Stefan O. Schönland, MD, Suzanne Lentzsch, MD PhD, M. Teresa Cibeira, MD PhD, Roman Hajek, Prof, MD PhD, Arnaud Jaccard, MD PhD, Krzysztof Jamroziak, MD PhD, Eftathios Kastritis, Vaishali Sanchorawala, MD, Fredrik H. Schjesvold, MD PhD, Ashutosh D Wechalekar, MBBS, MD FRCP, FRCPath, DM, Sara Thuresson, MSc, Johan Harmenberg, MD PhD, Catriona Byrne, RN, Giampaolo Merlini, MD

Blood (2019) 134 (Supplement_1): 3163.

https://doi.org/10.1182/blood-2019-124244

Published: 2019

Journal Articles

Myeloma Heterogeneity within Its Complex Immune Ecosystem

Jana Jakubikova, PhD, Danka Cholujova, PhD, Gabor Beke, PhD, Zachary R Hunter, PhD, Teru Hideshima, MD PhD, Merav Leiba, MD, Krzysztof Jamroziak, MD PhD, Paul G. Richardson, MD, Eftathios Kastritis, David M. Dorfman, MD PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 4354.

https://doi.org/10.1182/blood-2019-132193

Published: 2019

Journal Articles

Natural History of Skeletal Related Events in Patients with Multiple Myeloma Who Received First- and Second- Line Therapy with Novel Agents: Results from a Single Center Analysis in 620 Patients

Evangelos Terpos, MD PhD, Nikolaos Kanellias, MD, Eftathios Kastritis, Maria Gavriatopoulou, MD, Vassilis Koutoulidis, MD, Ioannis Ntanasis-Stathopoulos, MD, Aristea-Maria Papanota, MD, Despina Fotiou, MD, Magdalini Migkou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Panagiotis Malandrakis, MD, Tina Bagratuni, PhD, Maria Roussou, MD, Lia A. Moulopoulos, MD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 4326.

https://doi.org/10.1182/blood-2019-123606

Published: 2019

Journal Articles

A Molecular Signature of Three tRNA-Derived RNA Fragments May Discriminate Smoldering from Symptomatic Multiple Myeloma Patients

Paraskevi Karousi, BSc, Aristea-Maria Papanota, MD, Pinelopi I Artemaki, BSc, Christine Liacos, MSc, Christos K. Kontos, PhD, Dimitris Patseas, BSc, Aikaterini-Anna Liosi, BSc, Nefeli Mavrianou-Koutsoukou, BSc, Maria-Anna Kalioraki, BSc, Despina Fotiou, BMBS, MA, Ioannis Ntanasis-Stathopoulos, MD, Magdalini Migkou, MD, Panagiotis Malandrakis, MD, Maria Gavriatopoulou, MD, Eftathios Kastritis, Evangelos Terpos, MD PhD, Andreas Scorilas, PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 5528.

https://doi.org/10.1182/blood-2019-129082

Published: 2019

Journal Articles

The Clinical Significance of a Novel microRNA Signature in Multiple Myeloma

Pinelopi I Artemaki, BSc, Aristea-Maria Papanota, MD, Paraskevi Karousi, BSc, Christine Liacos, MSc, Christos K. Kontos, PhD, Dimitris Patseas, BSc, Maria-Alexandra Papadimitriou, BSc, Evangelos Eleutherakis-Papaiakovou, MD, Margaritis Avgeris, PhD, Nikolaos Kanellias, MD, Tina Bagratuni, PhD, Maria Roussou, MD, Ioanna Dialoupi, MD, Eftathios Kastritis, Maria Gavriatopoulou, MD, Meletios A. Dimopoulos, MD, Andreas Scorilas, PhD, Evangelos Terpos, MD PhD

Blood (2019) 134 (Supplement_1): 5529.

https://doi.org/10.1182/blood-2019-129218

Published: 2019

Journal Articles

Efficacy of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: An Interim Analysis of a Phase 2 Study (the DARE Study)

Eftathios Kastritis, Evangelos Terpos, MD PhD, Argiris Symeonidis, MD PhD, Sosana Delimpasi, MD, Michele Cavo, Elena Zamagni, MD, Eirini Katodritou, MD, Barbara Gamberi, MD, Marie-Christine Kyrtsonis, MD PhD, Maria Gavriatopoulou, MD, Maria Roussou, MD, Despina Fotiou, MD, Evdoxia Hatjiharissi, Nikolaos Kanellias, MD, Magdalini Migkou, MD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1881.

https://doi.org/10.1182/blood-2019-124630

Published: 2019

Journal Articles

Impact of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor; Interim Analysis of a Phase 2 Study (the REBUILD Study)

Evangelos Terpos, MD PhD, Eftathios Kastritis, Evdoxia Hatjiharissi, Eirini Katodritou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Evgenia Verrou, MD, Maria Gavriatopoulou, MD, Alexandros Leonidakis, PhD, Ioannis Ntanasis-Stathopoulos, MD, Sosana Delimpasi, MD, Marie-Christine Kyrtsonis, MD PhD, Maria Papaioannou, Argiris Symeonidis, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1837.

https://doi.org/10.1182/blood-2019-124638

Published: 2019

Journal Articles

Clinical Impact of an Early Response and of Early Initiation of Salvage Therapy in Patients with Systemic Light Chain (AL) Amyloidosis

Eftathios Kastritis, Maria Gavriatopoulou, MD, Maria Roussou, MD, Magdalini Migkou, MD, Despina Fotiou, BMBS, MA, Ioanna Dialoupi, MD, Nikolaos Kanellias, MD, Evangelos Eleutherakis-Papaiakovou, MD, Foteini Theodorakakou, MD, Asimina Papanikolaou, MD, Erasmia Psimenou, MD, Kimon Stamatelopoulos, MD, Efstathios Manios, MD, Maria Irini Tselegkidi, MD, Argyrios Ntalianis, MD, Stavroula Giannouli, MD PhD, Evangelos Terpos, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1894.

https://doi.org/10.1182/blood-2019-128208

Published: 2019

Journal Articles

Renal Pathology in Patients with Monoclonal Gammopathy or Multiple Myeloma: Monoclonal Immunoglobulins Are Not Always the Cause

Eftathios Kastritis, Nikolaos Kanellias, MD, Foteini Theodorakakou, MD, Erasmia Psimenou, MD, Charikleia Gakiopoulou, MD, Smaragdi Marinaki, Maria Roussou, MD, Maria Gavriatopoulou, MD, Magdalini Migkou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Panagiotis Malandrakis, MD, Evangelos Terpos, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1776.

https://doi.org/10.1182/blood-2019-126385

Published: 2019

Journal Articles

Daratumumab Monotherapy in Previously Untreated High-Risk Patients with Stage 3B Light Chain (AL) Amyloidosis: A Phase II Multicenter Study By European Myeloma Network (EMN)

Eftathios Kastritis, Monique C. Minnema, Meletios A. Dimopoulos, MD, Giampaolo Merlini, MD, Pieter Sonneveld, Giovanni Palladini, MD PhD

Blood (2019) 134 (Supplement_1): 1868.

https://doi.org/10.1182/blood-2019-126524

Published: 2019

Journal Articles

Pulmonary Function Tests Reveal Unrecognized Lung Dysfunction and Have Independent Prognostic Significance in Patients with Systemic AL Amyloidosis

Eftathios Kastritis, Georgia Trakada, MD, Despina Fotiou, BMBS, MA, Magdalini Migkou, MD, Maria Gavriatopoulou, MD, Nikolaos Kanellias, MD, Evangelos Eleutherakis-Papaiakovou, MD, Ioanna Dialoupi, MD, Ioannis Ntanasis-Stathopoulos, MD, Despina Mparmparousi, Aikaterini Xirokosta, Evangelos Terpos, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1842.

https://doi.org/10.1182/blood-2019-125877

Published: 2019

NARROW

Synergistic Effect of Carfilzomib and Metformin in Vascular Plasticity; The Emerging Role of Autophagy

Next Generation Flow Cytometry Provides a Standardized, Highly Sensitive and Informative Method for the Analysis of Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma: A Single Center Study in 182 Patients

The Genomic and Transcriptomic Landscape of Double-Refractory Multiple Myeloma

Outcomes of Patients with t(11;14) Multiple Myeloma: An International Myeloma Working Group Multicenter Study

Longitudinal T Cell Immunoprofiling of Patients with Relapsed and/or Refractory Myeloma Who Receive Daratumumab Monotherapy: A Subanalysis of a Phase 2 Study (the REBUILD Study)

Consolidation with Carfilzomib, Lenalidomide and Dexamethasone (KRd) Following ASCT Results in High Rates of Minimal Residual Disease Negativity and Improves Bone Metabolism, in the Absence of Bisphosphonates, Among Newly Diagnosed Patients with Multiple Myeloma

Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients

Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Is a Renal Biomarker with Potential Clinical Applications in Monoclonal Gammopathy of Renal Significance (MGRS)

High-Dimensional Heterogeneity of Waldenström Macroglobulinemia within Its Immune Tumor Microenvironment

OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis

Myeloma Heterogeneity within Its Complex Immune Ecosystem

Natural History of Skeletal Related Events in Patients with Multiple Myeloma Who Received First- and Second- Line Therapy with Novel Agents: Results from a Single Center Analysis in 620 Patients

A Molecular Signature of Three tRNA-Derived RNA Fragments May Discriminate Smoldering from Symptomatic Multiple Myeloma Patients

The Clinical Significance of a Novel microRNA Signature in Multiple Myeloma

Efficacy of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: An Interim Analysis of a Phase 2 Study (the DARE Study)

Impact of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor; Interim Analysis of a Phase 2 Study (the REBUILD Study)

Clinical Impact of an Early Response and of Early Initiation of Salvage Therapy in Patients with Systemic Light Chain (AL) Amyloidosis

Renal Pathology in Patients with Monoclonal Gammopathy or Multiple Myeloma: Monoclonal Immunoglobulins Are Not Always the Cause

Daratumumab Monotherapy in Previously Untreated High-Risk Patients with Stage 3B Light Chain (AL) Amyloidosis: A Phase II Multicenter Study By European Myeloma Network (EMN)

Pulmonary Function Tests Reveal Unrecognized Lung Dysfunction and Have Independent Prognostic Significance in Patients with Systemic AL Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only